MONTIVIB LC SYRUPLEVOCETIRIZINE 2.5mg. IP + MONTELUKAST 4mg. IP

Montivib LC Syrup is a 60ml anti-allergic syrup with Levocetirizine 2.5 mg and Montelukast 4 mg for allergic rhinitis, urticaria and asthma. Main uses: relief of symptoms of seasonal allergic rhinitis such as sneezing, runny or blocked nose and watery eyes, in patients who do not respond to or cannot take other therapies; relief of symptoms of perennial (all-year) allergic rhinitis, in patients who do not respond to or cannot take other therapies; treatment of the uncomplicated skin symptoms of chronic idiopathic urticaria, including itching and hives; prophylaxis and long-term treatment of asthma in young children; long-term management of allergic symptoms that affect the nose and the airways together.

Common side effects of Montivib LC Syrup include drowsiness or sleepiness; fever; headache; cough; sore throat or runny nose; abdominal pain. Get medical help at once if you notice serious neuropsychiatric events such as agitation, aggression, depression, sleep disturbances and suicidal thoughts or behaviour; severe allergic reactions including swelling of the face or throat and anaphylaxis; urinary retention (unable to pass urine).

Montivib LC Syrup contains Levocetirizine 2.5 mg + Montelukast 4 mg. The right dose and how long to take it depend on the condition, age and other medicines, so use Montivib LC Syrup only as your doctor advises.

The MRP of Montivib LC Syrup is ₹118 for a pack of 60ml. For chemists and distributors, the PTR is ₹89.9 and the PTS is ₹80.91.

Montivib LC Syrup contains Levocetirizine 2.5 mg + Montelukast 4 mg. It comes in a pack of 60ml.

Levocetirizine works by blocking histamine at H1 receptors in the body, which helps ease sneezing, a runny nose, itching and watery eyes. Montelukast works by blocking cysteinyl leukotrienes, chemicals that swell and tighten the airways and nasal passages. The two ingredients act on different parts of the allergic response.

Must not be used if the patient is allergic to levocetirizine, cetirizine, montelukast or any ingredient of the syrup. Must not be used in patients with end-stage kidney disease (creatinine clearance below 10 mL/min) or those on haemodialysis. Must not be used in children 6 months to 11 years of age who have impaired kidney function. Must not be used to treat a sudden or acute asthma attack; a rescue medicine should be kept available. Patients with known aspirin sensitivity must continue to avoid aspirin and other non-steroidal anti-inflammatory medicines while taking montelukast.

Montivib LC Syrup is a brand of Vibcare Pharma, sold through its Prima division. It is available for PCD pharma franchise and distribution in India; use the Send Enquiry or WhatsApp button on this page to ask about availability and terms.